Effect of Elagolix in comparison to Dienogest in the treatment of symptomatic adenomyosis
Rattachement africain : bd, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Adenomyosis, a benign gynecological disorder, is diagnosed with increasing frequency in infertile patients since women delay their first pregnancy. Common symptoms of adenomyosis are dysmenorrhea and heavy menstrual bleeding (HMB), resulting in poor quality of life. Elagolix, the oral GnRH antagonist, acts by reducing the occurrence of ectopic endometrial implants in the myometrium. It diminishes uterine volume, reduces dysmenorrhea and heavy bleeding, and improves fertility outcomes. Dienogest, a synthetic oral progestin highly selective for progesterone receptors, reduces the painful symptoms in women with adenomyosis. The aim or this study was to compare the effect of Elagolix with Dienogest in the treatment of symptomatic adenomyosis. Methods: This randomized controlled trial was conducted in the department of reproductive endocrinology and infertility, Bangabandhu Sheikh Mujib medical university (BSMMU), Dhaka, from January 2024 to December 2024. A total of 58 participants with symptomatic adenomyosis were randomly assigned to 2 groups (n=29). Each group received either Elagolix (200 mg) or Dienogest (2 mg) once daily for 3 months. Results: Compared between the two groups, post-treatment mean changes of VAS score (6.25±1.83 vs 4.84±1.56), hemoglobin (-1.21±0.97 vs-0.20±0.56), and median uterine volume (5.1 vs 1.2) were significantly higher in the Elagolix group than the Dienogest group. HMB was also significantly reduced (3.7% vs 23.1%) in the Elagolix than the Dienogest group after 3 months of treatment. Conclusion: Elagolix significantly reduced VAS score, HMB, and uterine volume in symptomatic adenomyosis compared to Dienogest.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effect of Elagolix in comparison to Dienogest in the treatment of symptomatic adenomyosis
- Date Crossref
- 26/06/2025
- Éditeur
- Medip Academy
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Directorate General of Health Services pays non établi dans la noticeOrganisme public
-
New Cross Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
The Royal Wolverhampton NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Mymensingh Medical College Hospital pays non établi dans la noticeÉtablissement de santé
-
Department of Reproductive Endocrinology and Infertility (OSD) pays non établi dans la noticeInstitution
-
Bangladesh Medical University Department of Reproductive Endocrinology and Infertility pays non établi dans la noticeUniversité ou école supérieure
-
Mymensingh Medical College and Hospital Department of Gynecology pays non établi dans la noticeUniversité ou école supérieure
Directorate General of Health Services, Department of Urology — New Cross Hospital et The Royal Wolverhampton NHS Trust, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.